A Phase 1, Open-Label Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-64264681 in Participants with Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

2024-512686-13-00 Protocol 64264681LYM1001 Human pharmacology (Phase I) - Other Ended

Start 28 Jan 2021 · End 28 May 2025 · Status Ended · 1 EU/EEA countries · 4 sites · Protocol 64264681LYM1001

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ended
Participants planned 41
Countries 1
Sites 4

non-Hodgkin lymphoma and chronic lymphocytic leukemia

Key facts

Sponsor
Janssen Cilag International
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Trial duration
28 Jan 2021 → 28 May 2025
Decision date (initial)
2024-07-09
Transition trial
Yes
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

External identifiers

EU CT number
2024-512686-13-00
EudraCT number
2019-003194-25

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

non-Hodgkin lymphoma and chronic lymphocytic leukemia

VersionLevelCodeTermSystem organ class
23.1 LLT 10084346 B-cell non-Hodgkin´s lymphoma 100000004848
21.0 LLT 10008976 Chronic lymphocytic leukemia 10029104

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Janssen Cilag International

Sponsor organisation
Janssen Cilag International
Address
Turnhoutseweg 30
City
Beerse
Postcode
2340
Country
Belgium

Scientific contact point

Organisation
Janssen Cilag International
Contact name
CTIS Point of Contact

Public contact point

Organisation
Janssen Cilag International
Contact name
CTIS Point of Contact

Locations

1 EU/EEA country · 4 investigational sites

By country

CountryMS statusPlanned subjectsSites
Poland Ended 16 4
Rest of world
United States, Ukraine, Moldova, Republic of, Taiwan, Georgia, United Kingdom
25

Investigational sites

Poland

4 sites · Ended
Uniwersyteckie Centrum Kliniczne
Uniwersyteckie Centrum Kliniczne, Ul. Mariana Smoluchowskiego 17, 80-214, Gdansk
Pratia S.A.
Pratia MCM, Ul. Pana Tadeusza 2, 30-727, Cracow
Pratia Hematologia Sp. z o.o.
Pratia Hematologia Sp. z o.o., Ul. Tadeusza Kosciuszki 92, 40-519, Katowice
Pratia S.A.
Centrum Medyczne Pratia Poznan, Ul. Poznanska 14, 60-185, Skorzewo

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Poland 2021-01-28 2025-01-29 2021-01-28 2023-03-07

Application history

1 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-06-13 Poland Acceptable
2024-07-05
2024-07-09